Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Polyunsaturated fatty acids are important for normal growth and development. One type, called omega-3 fatty acids (found in fish, fish oil, and some other foods), may affect the growth of abnormal breast cells.

PURPOSE: This randomized pilot trial is studying how well omega-3 fatty acids work in treating women with newly diagnosed ductal carcinoma in situ and/or atypical ductal hyperplasia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

NCT01869764

Ductal Breast Carcinoma in Situ Lobular Breast Carcinoma in Situ Male Breast Cancer +6 more

COMPLETED PHASE2

Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer

NCT00114296

Breast Cancer

UNKNOWN NA

Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors

NCT02352779

Breast Carcinoma Cancer Fatigue

COMPLETED NA

Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention

NCT01282580

Breast Cancer

COMPLETED PHASE1

Breast, Omega 3 Free Fatty Acid, Ph 0

NCT02996240

Breastcancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* To determine the effect of omega-3 fatty acids on markers of breast cancer progression in women with newly diagnosed ductal carcinoma in situ and/or atypical ductal hyperplasia.
* To determine the effect of omega-3 fatty acids on specific targets identified by microarray in breast cancer cells and in primary cultures from benign and malignant breast tissue biopsies.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8 weeks.
* Arm II: Patients receive oral placebo olive oil capsules 3 times daily for up to 8 weeks.

Patients complete questionnaires at baseline, weekly during study treatment, at the completion of study treatment, and then at 30 days after completion of study treatment. These questionnaires include the Fish Oil Adverse Event Questionnaire, the Diet and Family History Questionnaire, the Changes to Diet and Medications Questionnaire, and the Post-Intervention Questionnaire.

Patients undergo blood, urine, nipple aspirate, and tissue sample collection at baseline and after completion of study treatment for translational research studies. Blood samples are analyzed for genetic markers for breast cancer risk and progression by microarray analysis and red blood cell (RBC) fatty acids. Nipple aspirate samples are analyzed for fatty acids to determine the extent to which omega-3 fatty acid supplementation alters the fatty acid profile of breast tissue. Tissue samples are analyzed for the presence of ductal carcinoma in situ and/or atypical ductal hyperplasia or invasive cancer. Leftover blood, urine, nipple aspirate, and tissue samples are stored for future research studies.

After completion of study treatment, patients are followed at 30 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Precancerous Condition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I

Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8 weeks.

Group Type EXPERIMENTAL

omega-3 fatty acid

Intervention Type DIETARY_SUPPLEMENT

Oral, 3 times daily

Arm II

Patients receive oral placebo olive oil capsules 3 times daily for up to 8 weeks.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

Oral, 3 times daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

omega-3 fatty acid

Oral, 3 times daily

Intervention Type DIETARY_SUPPLEMENT

placebo

Oral, 3 times daily

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Biopsy confirmed diagnosis of any of the following:

* Ductal carcinoma in situ (DCIS) and/or atypical ductal hyperplasia (ADH)
* DCIS with a component of invasive carcinoma
* ADH with a component of invasive carcinoma
* DCIS and ADH with a component of invasive carcinoma
* Newly diagnosed disease
* No pure invasive breast cancer on biopsy without a component of DCIS or ADH
* Hormone receptor status not specified

PATIENT CHARACTERISTICS:

* Female
* Menopausal status not specified
* Not pregnant
* Negative pregnancy test
* Speaks English or Spanish
* No allergy to fish oil or olive oil
* No condition that, in the opinion of the study clinician, would make participation in the study harmful to the patient

PRIOR CONCURRENT THERAPY:

* No concurrent therapeutic anticoagulation
* No concurrent use of fish oil \> 1 g/day

Minimum Eligible Age

21 Years

Maximum Eligible Age

120 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No